Market closed

Celularity/$CELU

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Celularity

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.

Ticker

$CELU

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Florham Park, United States

Employees

120

Website

www.celularity.com

Celularity Metrics

BasicAdvanced

$47M

-

-$1.66

0.64 -

Price and volume

Market cap

$47M

Beta

0.64

52-week high

$7.97

52-week low

$1.30

Average daily volume

186K

Financial strength

Current ratio

0.19

Quick ratio

0.117

Long term debt to equity

153.073

Total debt to equity

399.659

Interest coverage (TTM)

-7.81%

Management effectiveness

Return on assets (TTM)

-17.45%

Return on equity (TTM)

-147.50%

Valuation

Price to revenue (TTM)

0.907

Price to book

2.63

Price to tangible book (TTM)

147.28

Price to free cash flow (TTM)

-3.357

Growth

Revenue change (TTM)

225.94%

Earnings per share change (TTM)

-84.79%

3-year revenue growth (CAGR)

34.70%

3-year earnings per share growth (CAGR)

-58.17%

What the Analysts think about Celularity

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Celularity stock.

Celularity Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Celularity Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Celularity News

AllArticlesVideos

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

GlobeNewsWire·1 month ago

Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

GlobeNewsWire·1 month ago

Celularity Inc. Announces Receipt of Nasdaq Notification

GlobeNewsWire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CELU

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Celularity stock?

Celularity (CELU) has a market cap of $47M as of January 15, 2025.

What is the P/E ratio for Celularity stock?

The price to earnings (P/E) ratio for Celularity (CELU) stock is 0 as of January 15, 2025.

Does Celularity stock pay dividends?

No, Celularity (CELU) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Celularity dividend payment date?

Celularity (CELU) stock does not pay dividends to its shareholders.

What is the beta indicator for Celularity?

Celularity (CELU) has a beta rating of 0.64. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.